» Articles » PMID: 27378473

Fourth Consensus of the International Society for Premenstrual Disorders (ISPMD): Auditable Standards for Diagnosis and Management of Premenstrual Disorder

Abstract

Whilst professional bodies such as the Royal College and the American College of Obstetricians and Gynecologists have well-established standards for audit of management for most gynaecology disorders, such standards for premenstrual disorders (PMDs) have yet to be developed. The International Society of Premenstrual Disorders (ISPMD) has already published three consensus papers on PMDs covering areas that include definition, classification/quantification, clinical trial design and management (American College Obstetricians and Gynecologists 2011; Brown et al. in Cochrane Database Syst Rev 2:CD001396, 2009; Dickerson et al. in Am Fam Physician 67(8):1743-1752, 2003). In this fourth consensus of ISPMD, we aim to create a set of auditable standards for the clinical management of PMDs. All members of the original ISPMD consensus group were invited to submit one or more auditable standards to be eligible in the inclusion of the consensus. Ninety-five percent of members (18/19) responded with at least one auditable standard. A total of 66 auditable standards were received, which were returned to all group members who then ranked the standards in order of priority, before the results were collated. Proposed standards related to the diagnosis of PMDs identified the importance of obtaining an accurate history, that a symptom diary should be kept for 2 months prior to diagnosis and that symptom reporting demonstrates symptoms in the premenstrual phase of the menstrual cycle and relieved by menstruation. Regarding treatment, the most important standards were the use of selective serotonin reuptake inhibitors (SSRIs) as a first line treatment, an evidence-based approach to treatment and that SSRI side effects are properly explained to patients. A set of comprehensive standards to be used in the diagnosis and treatment of PMD has been established, for which PMD management can be audited against for standardised and improved care.

Citing Articles

Association between maternal overprotection and premenstrual disorder: a machine learning based exploratory study.

Tsuyuki K, Egawa M, Ohsuga T, Ueda A, Shimada K, Ueno T Biopsychosoc Med. 2025; 19(1):4.

PMID: 39994774 PMC: 11849209. DOI: 10.1186/s13030-025-00326-y.


The experiences and psychological impact of living with premenstrual disorders: a systematic review and thematic synthesis.

Brown D, Smith D, Osborn E, Wittkowski A Front Psychiatry. 2024; 15:1440690.

PMID: 39286397 PMC: 11402655. DOI: 10.3389/fpsyt.2024.1440690.


Practical diagnosis and treatment of premenstrual syndrome and premenstrual dysphoric disorder by psychiatrists and obstetricians/gynecologists in Japan.

Yoshimi K, Inoue F, Odai T, Shirato N, Watanabe Z, Otsubo T PCN Rep. 2024; 3(3):e234.

PMID: 39149567 PMC: 11325828. DOI: 10.1002/pcn5.234.


Premenstrual syndrome: new insights into etiology and review of treatment methods.

Modzelewski S, Oracz A, Zukow X, Ilendo K, Sledzikowka Z, Waszkiewicz N Front Psychiatry. 2024; 15:1363875.

PMID: 38716118 PMC: 11075635. DOI: 10.3389/fpsyt.2024.1363875.


Use of Vitex agnus-castus in patients with menstrual cycle disorders: a single-center retrospective longitudinal cohort study.

Holler M, Steindl H, Abramov-Sommariva D, Kleemann J, Loleit A, Abels C Arch Gynecol Obstet. 2024; 309(5):2089-2098.

PMID: 38393671 PMC: 11018691. DOI: 10.1007/s00404-023-07363-4.